Stock info Moderna Inc | Filter Basic-Info
Stock: Moderna Inc (US broad)
| Last Price | 103.44 | Max Price | 141.14 |
| Min Price | 69.51 | 1 Year return | -42.41 |
| Sector | Health Care | Subsector | Biotechnology |
Loading...
Contact info:Country: USA
Sector Review Moderna Inc
Loading...
| Year | Turnover | Total sector | Market share |
|---|---|---|---|
| 2019 | 60 | 141,925 | 0.04 % |
| 2020 | 803 | 170,231 | 0.47 % |
| 2021 | 18,471 | 252,886 | 7.30 % |
| 2022 | 19,263 | 238,500 | 8.08 % |
| 2023 | 0 | 0 | 0.00 % |
Advice Moderna Inc
No Records Found
News Moderna Inc
Moderna plans to invest ~€500M in Spain
Moderna (NASDAQ:MRNA) intends to invest ~€500M in Spain and open a laboratory to strengthen its vaccine production, Spain's Prime Minister Pedro Sanchez said in a tweet June 14.
Sanchez said in a tweet that he met with Moderna's Vice President Dan Staner...
Indonesia approves Moderna's COVID-19 jab for emergency use
Indonesia has authorized Moderna's (NASDAQ:MRNA) COVID-19 vaccine for emergency use.
The country will receive 4M vaccine doses as part of the COVAX global-sharing scheme.
In addition, The Netherlands will also donate 3M vaccine doses, said Indonesian...
Moderna targets 600 million doses of COVID-19 booster shots with new Lonza deal
Moderna (MRNA) hit a 52-week high today on the news of an additional agreement with Swiss contract manufacturer Lonza (OTCPK:LZAGY +0.3%) to ramp up the drug substance manufacturing for its global supply chain.
The highlight of the announcement was the commissioning...
Moderna cutting vaccine deliveries to Canada, but Pfizer adding doses
Canada will receive just 650K COVID-19 shots from Moderna (NASDAQ:MRNA) instead of a previously anticipated 1.2M doses this month as the company deals with production issues at European facilities, according to CBC.
However, Prime Minister Justin Trudeau...
Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA
(mRNA) therapeutics and vaccines, today highlighted the publication of antibody persistence data out to 6 months following the second dose of the
Moderna COVID-19 Vaccine in The NewEngland...
Annual reports Moderna Inc
No Records Found
Profile Moderna Inc
No Records Found
Results Moderna Inc
| Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|---|
| Revenue |
0
|
108
|
206
|
135
|
60
|
803
|
| Costs |
0
|
339
|
476
|
537
|
574
|
1,550
|
| Profit |
0
|
-230
|
-270
|
-402
|
-514
|
-747
|
| Margin of profit |
0.0
|
-212.46
|
-131.10
|
-297.52
|
-853.71
|
-92.99
|
| ROI |
0.0
|
-27.36
|
-43.15
|
-26.26
|
-43.75
|
-29.17
|
Balance Moderna Inc
| Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|---|
| Equity |
0
|
842
|
625
|
1,530
|
1,175
|
2,561
|
| Debt |
0
|
575
|
459
|
432
|
415
|
4,775
|
| Total assets |
0
|
1,417
|
1,084
|
1,962
|
1,589
|
7,337
|
| Solvency |
0.0
|
59.40
|
57.66
|
77.99
|
73.91
|
34.91
|
| Cash |
0
|
1,058
|
756
|
1,521
|
1,103
|
4,608
|
| Cashflow |
0
|
67
|
-331
|
-331
|
-459
|
2,027
|
| Employees |
0
|
0
|
0
|
0
|
0
|
|
| Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
| Cashflow / Debt |
0.0
|
0.12
|
-0.72
|
-0.77
|
-1.11
|
0.42
|
Details Moderna Inc
| Details |
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|
| Price |
0.0
|
0.0
|
0.0
|
15.27
|
19.56
|
| Eps |
-0.71
|
-0.83
|
-1.22
|
-1.55
|
-1.96
|
| Price/earnings-ratio |
0.0
|
0.0
|
0.0
|
-9.85
|
-52.78
|
| Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
| Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
| Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
| Book value |
2.60
|
1.93
|
4.65
|
3.49
|
6.42
|
| Market to book |
0.0
|
0.0
|
0.0
|
0.23
|
0.06
|
| Cashflow per stock |
0.21
|
-1.02
|
-1.01
|
-1.36
|
5.08
|
| Stocks |
324
|
324
|
329
|
337
|
399
|
| Market Cap |
0.00
|
0.00
|
0.00
|
5.138.92
|
41.250.63
|
Dividend Moderna Inc
Price info Moderna Inc
|
Date
|
Price
|
|---|---|
|
18 Apr 2024
|
103.44
|
|
17 Apr 2024
|
103.79
|
|
09 Apr 2024
|
105.09
|
|
05 Apr 2024
|
102.27
|
|
03 Apr 2024
|
103.61
|
|
30 Mar 2024
|
106.56
|
|
22 Mar 2024
|
104.09
|
|
18 Mar 2024
|
104.26
|
|
15 Mar 2024
|
103.46
|
|
12 Mar 2024
|
111.98
|
|
11 Mar 2024
|
103.03
|
|
09 Mar 2024
|
103.03
|
|
07 Mar 2024
|
98.10
|
|
01 Mar 2024
|
92.24
|
|
29 Feb 2024
|
97.48
|
|
27 Feb 2024
|
94.02
|
|
22 Feb 2024
|
87.59
|
|
21 Feb 2024
|
86.99
|
|
20 Feb 2024
|
88.37
|
|
15 Feb 2024
|
85.95
|
|
14 Feb 2024
|
85.37
|
|
13 Feb 2024
|
89.00
|
|
09 Feb 2024
|
93.66
|
|
08 Feb 2024
|
99.30
|
|
07 Feb 2024
|
100.03
|
|
06 Feb 2024
|
95.49
|
|
05 Feb 2024
|
97.50
|
|
01 Feb 2024
|
101.05
|
|
31 Jan 2024
|
102.47
|
|
30 Jan 2024
|
104.84
|
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
©2024 ValueSpectrum. All Rights Reserved
Developed and maintained by 